![]() Owusu Obeng A, Scott SA, Kaszemacher T, Ellis SB, Mejia A, Gomez A, Nadukuru R, Abul-Husn NS, Vega A, Waite E, Gottesman O, Cho J, Bottinger EP. An efficient genotyper and star-allele caller for pharmacogenomics. Hari A, Zhou Q, Gonzaludo N, Harting J, Scott SA, Qing Q, Scherer S, Sahinalp SC, Numanagić I. Re-envisioning community genetics: Community empowerment in preventive genomics. Wand H, Martschenko DO, Smitherman A, Michelson S, Pun T, Witte JS, Scott SA, Cho MK, Ashley EA, Preventive Genomics Program Co-Design Working Group. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4 and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. (* equal contribution)īousman CA*, Stevenson JM*, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical pharmacogenomic MT-RNR1 screening for aminoglycoside-induced ototoxicity and the post-test counseling conundrum. Rigobello R*, Shaw J*, Ilg D*, Zimmerman R, Edelmann L, Kornreich R, Scott SA, Cody N. Response to the FDA decision regarding DPYD testing prior to fluoropyrimidine chemotherapy. Hertz DL, Smith DM, Scott SA, Patel JN, Hicks JK. CYP3A4 and CYP3A5 genotyping recommendations: A joint consensus recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE. The Genetic Testing Reference Materials (GeT-RM) Coordination Program: Over 10 years of support for pharmacogenomic testing. Two epilepsy-associated variants in KCNA2 (KV1.2) at position H310 oppositely affect channel functional expression. Viñas TM, Prakash V, Lindström SH, Wang K, Pozzi S, Scott SA, Spiteri E, Stevenson DA, Ashley E, Gunnarsson C, Pantazis A. Pharmacogenomic knowledge and awareness among diverse patients treated with angiotensin converting enzyme inhibitors. Naik H, O’Connor MY, Sanderson SC, Pinnell N, Dong M, Wiegand A, Owusu Obeng A, Abul-Husn NS, Scott SA. She has been a frequent collaborator with the SCOTT LAB through student mentoring, and both clinical and educational pharmacogenomic research projects. Her research interests include developing and evaluating PROs for genetic disorders and genomics, in particular assessing PROs as outcomes for clinical trials, pharmacogenomic implementation, and genetic counseling education and processes, as well as utilizing digital health technologies to improve clinical care, genetic counseling, patient reporting, trial efficacy, and outcomes. ![]() ![]() She is a Board certified genetic counselor and clinical researcher with expertise in the inborn errors of heme biosynthesis, porphyrias, lysosomal storage disorders and pharmacogenomics, and research expertise in clinical trials, patient reported outcomes (PROs), qualitative methods, and study design. Hetanshi NAIK is an Associate Professor in the Department of Genetics at Stanford and the Research Director of the MS Program in Human Genetics and Genetic Counseling. His research interests are focused on translational molecular biology, particularly in the areas of pharmacogenomics, cytogenomics, epigenomics and genomic medicine implementation, and he considers himself fortunate to work with the people that he does. SCOTT is currently the Director of the Stanford Medicine Clinical Genomics Laboratory and Professor in the Department of Pathology at Stanford University. In the Sema4 Laboratory he was involved in high-complexity clinical molecular testing, including pharmacogenomics, cytogenomics, and PacBio long-read HiFi sequencing applications. His interest in medical genetics and molecular pathology prompted postdoctoral American Board of Medical Genetics and Genomics (ABMGG) training in Clinical Molecular Genetics and Clinical Cytogenetics and Genomics at the Icahn School of Medicine at Mount Sinai and Board certification in both specialties. from the University of Saskatchewan, Canada, under the mentorship of hematopathologist Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |